284 related articles for article (PubMed ID: 30648269)
1. PTPRD: neurobiology, genetics, and initial pharmacology of a pleiotropic contributor to brain phenotypes.
Uhl GR; Martinez MJ
Ann N Y Acad Sci; 2019 Sep; 1451(1):112-129. PubMed ID: 30648269
[TBL] [Abstract][Full Text] [Related]
2. Substrate-selective positive allosteric modulation of PTPRD's phosphatase by flavonols.
Henderson IM; Marez C; Dokladny K; Smoake J; Martinez M; Johnson D; Uhl GR
Biochem Pharmacol; 2022 Aug; 202():115109. PubMed ID: 35636503
[TBL] [Abstract][Full Text] [Related]
3. Cocaine reward is reduced by decreased expression of receptor-type protein tyrosine phosphatase D (PTPRD) and by a novel PTPRD antagonist.
Uhl GR; Martinez MJ; Paik P; Sulima A; Bi GH; Iyer MR; Gardner E; Rice KC; Xi ZX
Proc Natl Acad Sci U S A; 2018 Nov; 115(45):11597-11602. PubMed ID: 30348770
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity studies of PTPRD phosphatase inhibitors identify a 7-cyclopentymethoxy illudalic acid analog candidate for development.
Henderson IM; Zeng F; Bhuiyan NH; Luo D; Martinez M; Smoake J; Bi F; Perera C; Johnson D; Prisinzano TE; Wang W; Uhl GR
Biochem Pharmacol; 2022 Jan; 195():114868. PubMed ID: 34863978
[TBL] [Abstract][Full Text] [Related]
5. Mouse Model for Protein Tyrosine Phosphatase D (
Drgonova J; Walther D; Wang KJ; Hartstein GL; Lochte B; Troncoso J; Uetani N; Iwakura Y; Uhl GR
Mol Med; 2015 Nov; 21(1):717-725. PubMed ID: 26181631
[TBL] [Abstract][Full Text] [Related]
6. Mice lacking Ptprd exhibit deficits in goal-directed behavior and female-specific impairments in sensorimotor gating.
Ho EV; Welch A; Thompson SL; Knowles JA; Dulawa SC
PLoS One; 2023; 18(5):e0277446. PubMed ID: 37205689
[TBL] [Abstract][Full Text] [Related]
7. Mutational and functional analysis of the tumor-suppressor PTPRD in human melanoma.
Walia V; Prickett TD; Kim JS; Gartner JJ; Lin JC; Zhou M; Rosenberg SA; Elble RC; Solomon DA; Waldman T; Samuels Y
Hum Mutat; 2014 Nov; 35(11):1301-10. PubMed ID: 25113440
[TBL] [Abstract][Full Text] [Related]
8. PTPRD (protein tyrosine phosphatase receptor type delta) is associated with restless legs syndrome.
Schormair B; Kemlink D; Roeske D; Eckstein G; Xiong L; Lichtner P; Ripke S; Trenkwalder C; Zimprich A; Stiasny-Kolster K; Oertel W; Bachmann CG; Paulus W; Högl B; Frauscher B; Gschliesser V; Poewe W; Peglau I; Vodicka P; Vávrová J; Sonka K; Nevsimalova S; Montplaisir J; Turecki G; Rouleau G; Gieger C; Illig T; Wichmann HE; Holsboer F; Müller-Myhsok B; Meitinger T; Winkelmann J
Nat Genet; 2008 Aug; 40(8):946-8. PubMed ID: 18660810
[TBL] [Abstract][Full Text] [Related]
9. Loss of the tyrosine phosphatase PTPRD leads to aberrant STAT3 activation and promotes gliomagenesis.
Ortiz B; Fabius AW; Wu WH; Pedraza A; Brennan CW; Schultz N; Pitter KL; Bromberg JF; Huse JT; Holland EC; Chan TA
Proc Natl Acad Sci U S A; 2014 Jun; 111(22):8149-54. PubMed ID: 24843164
[TBL] [Abstract][Full Text] [Related]
10. Family-based and population-based association studies validate PTPRD as a risk factor for restless legs syndrome.
Yang Q; Li L; Yang R; Shen GQ; Chen Q; Foldvary-Schaefer N; Ondo WG; Wang QK
Mov Disord; 2011 Feb; 26(3):516-9. PubMed ID: 21264940
[TBL] [Abstract][Full Text] [Related]
11. PTPRD is homozygously deleted and epigenetically downregulated in human hepatocellular carcinomas.
Acun T; Demir K; Oztas E; Arango D; Yakicier MC
OMICS; 2015 Apr; 19(4):220-9. PubMed ID: 25831062
[TBL] [Abstract][Full Text] [Related]
12. Polymorphism of receptor-type tyrosine-protein phosphatase delta gene in the development of non-alcoholic fatty liver disease.
Nakajima S; Tanaka H; Sawada K; Hayashi H; Hasebe T; Abe M; Hasebe C; Fujiya M; Okumura T
J Gastroenterol Hepatol; 2018 Jan; 33(1):283-290. PubMed ID: 28497593
[TBL] [Abstract][Full Text] [Related]
13. Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC.
Sun Y; Duan J; Fang W; Wang Z; Du X; Wang X; Li C; Cai S; Zhao J; Li S; Zhang L; Bai H; Wang J
BMC Med; 2021 Oct; 19(1):239. PubMed ID: 34615542
[TBL] [Abstract][Full Text] [Related]
14. The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers.
Veeriah S; Brennan C; Meng S; Singh B; Fagin JA; Solit DB; Paty PB; Rohle D; Vivanco I; Chmielecki J; Pao W; Ladanyi M; Gerald WL; Liau L; Cloughesy TC; Mischel PS; Sander C; Taylor B; Schultz N; Major J; Heguy A; Fang F; Mellinghoff IK; Chan TA
Proc Natl Acad Sci U S A; 2009 Jun; 106(23):9435-40. PubMed ID: 19478061
[TBL] [Abstract][Full Text] [Related]
15. PTPRD silencing by DNA hypermethylation decreases insulin receptor signaling and leads to type 2 diabetes.
Chen YT; Lin WD; Liao WL; Lin YJ; Chang JG; Tsai FJ
Oncotarget; 2015 May; 6(15):12997-3005. PubMed ID: 26079428
[TBL] [Abstract][Full Text] [Related]
16. Genetic validation study of protein tyrosine phosphatase receptor type D (PTPRD) gene variants and risk for antipsychotic-induced weight gain.
Maciukiewicz M; Gorbovskaya I; Tiwari AK; Zai CC; Freeman N; Meltzer HY; Kennedy JL; Müller DJ
J Neural Transm (Vienna); 2019 Jan; 126(1):27-33. PubMed ID: 30229349
[TBL] [Abstract][Full Text] [Related]
17. Genetic variants in PTPRD and risk of gestational diabetes mellitus.
Chen T; Xu J; Liu G; Liu H; Chen M; Qin Y; Wu W; Xia Y; Ji C; Guo X; Wen J; Wang X
Oncotarget; 2016 Nov; 7(46):76101-76107. PubMed ID: 27738328
[TBL] [Abstract][Full Text] [Related]
18. Deletion of Ptprd and Cdkn2a cooperate to accelerate tumorigenesis.
Ortiz B; White JR; Wu WH; Chan TA
Oncotarget; 2014 Aug; 5(16):6976-82. PubMed ID: 25138050
[TBL] [Abstract][Full Text] [Related]
19. Polymorphism in protein tyrosine phosphatase receptor delta is associated with the risk of clear cell renal cell carcinoma.
Du Y; Su T; Tan X; Li X; Xie J; Wang G; Shen J; Hou J; Cao G
Gene; 2013 Jan; 512(1):64-9. PubMed ID: 23069849
[TBL] [Abstract][Full Text] [Related]
20. Protein tyrosine phosphatase receptor delta acts as a neuroblastoma tumor suppressor by destabilizing the aurora kinase A oncogene.
Meehan M; Parthasarathi L; Moran N; Jefferies CA; Foley N; Lazzari E; Murphy D; Ryan J; Ortiz B; Fabius AW; Chan TA; Stallings RL
Mol Cancer; 2012 Feb; 11():6. PubMed ID: 22305495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
